off label glp-1 microdose glp 1 oral Microdosing agonists—using doses below FDA-approved levels for T2D GLP-1 Advanced Intra-Oral Spray, by
Description
and has participated on a data safety monitoring board/advisory board for Boehringer Ingelheim

BMC Complement

[13] recently reported that GLP-1 RAs are not associated with an increased risk of intestinal obstruction in patients with inflammatory bowel disease using Danish health registries

To put that in perspective, thats roughly 1-2 people out of every 100

TEXT ON-SCREEN: , 6
